SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000904454-24-000480
Filing Date
2024-08-22
Accepted
2024-08-22 18:44:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D - FILER IS WILDCAT AND ISSUER IS BIOMOTION s13d_082224-biomotion.htm SC 13D 70678
2 exhibit991.htm EX-99 5130
  Complete submission text file 0000904454-24-000480.txt   77505
Mailing Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106 212-468-5100
Wildcat Capital Management, LLC (Filed by) CIK: 0001582384 (see all company filings)

IRS No.: 453715536 | State of Incorp.: DE | Fiscal Year End: 1213
Type: SC 13D

Mailing Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871
Business Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871 972-8-6286005
Silexion Therapeutics Corp (Subject) CIK: 0002022416 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-94600 | Film No.: 241233127
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)